Recommendations on Subsequent Lines of Chemotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC)

It is recommended to first consider participating in clinical trials.

Some cancer cells have proteins on their surface called epidermal growth factor receptors (EGFRs). Gene changes known as mutations can produce abnormal EGFRs, causing cancer.

Beyond second line chemotherapy, erlotinib can be considered in patients for whom the presence of absence of such a mutation is unknown or in patients who do not have such a mutation and have not received EGFR tyrosine kinase inhibitor (TKI) treatment, a type of treatment that inhibits cancer-causing abnormal EGFRs. Erlotinib is a drug that blocks receptors that stimulate cancer to grow, preventing cancer cell growth.